The regenerative medicine business of Hitachi Chemical, headquartered in Japan, has announced that it has adopted the name Minaris Regenerative Medicine to represent its global contract development and manufacturing services business for the cell and gene therapy industry.

Minaris is derived from the Japanese word ‘mirai’ which means the future and the English word ‘miracle’. The name stands for the company’s commitment to constantly push the boundaries of what is possible and provide future miracles to patients. The vision of Minaris Regenerative Medicine is ‘creating future cell therapy miracles together’ and its mission is to ‘commit our experience to our clients, by providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being.’

The wholly-owned regional subsidiary companies and entities within Minaris Regenerative Medicine, encompassing a global footprint of over 200,000 square feet and an employee base of over 500, have adopted the same name:

• North America: Hitachi Chemical Advanced Therapeutics Solutions, LLC is renamed Minaris Regenerative Medicine, LLC, effective today
• Europe: Apceth Biopharma GmbH is renamed Minaris Regenerative Medicine GmbH, effective today
• Asia: Hitachi Chemical’s Yokohama regenerative medicine facility adopted the use of Minaris Regenerative Medicine as its brand name

Hitachi Chemical, the parent company of Minaris Regenerative Medicine, will be renamed Showa Denko Materials, Co., Ltd. on October 1, 2020, as announced previously.